StreetAlpha.app
Home › Stocks › ANEB

Anebulo Pharmaceuticals, Inc. (ANEB)

Members
LATEST PRICE

Anebulo develops selonabant, an experimental drug for treating cannabis toxicity, mainly aimed at children and emergency departments. For the quarter ended Dec 2025, ANEB reported EPS of -$0.05.

AI Auto Pilots
Is ANEB in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ANEB.

Key Stats

Last 12 months
Results
Net income
−$8.0M
EPS (diluted)
−$0.18
Valuation
Market cap
Price to sales
Dividend yield
Balance sheet
Cash & equivalents
$9.0M
At Dec 31
Shareholder equity
$7.9M
Shares outstanding
40.8M
At Feb 6
Fiscal year endsJune
ExchangeOTC
Financials history
FY2021: −$30.3M−$30.3MFY2021FY2022: −$6.8M−$6.8MFY2022FY2023: −$11.7M−$11.7MFY2023FY2024: −$8.2M−$8.2MFY2024FY2025: −$8.5M−$8.5MFY2025

From ANEB's SEC filings, latest 10-Q for the period ending Dec 31, 2025 (filed Feb 12). Last 12 months adds up the four latest quarters.

Next report
—
No date on file yet
Reported EPS
-$0.05
Quarter ended Dec 2025
Year ago EPS
-$0.09
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Mar 2024: -$0.06Mar '24Jun 2024: -$0.05Jun '24Sep 2024: -$0.08Sep '24Dec 2024: -$0.09Dec '24Mar 2025: -$0.04Mar '25Jun 2025: -$0.05Jun '25Sep 2025: -$0.05Sep '25Dec 2025: -$0.05Dec '25Latest -$0.05
Revenue by quarter
Not enough quarters on file yet.
StreetAlpha's call on ANEBStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Technical Analysis

Sample · made up numbers
SampleMade up numbers, showing what this section looks like for ANEB. AI Starter and AI Pro members see the real figures.Sign up freeSign in
Pullback inside a longer uptrend, nearing oversold

The stock is 8% below its 20 day and 6% below its 50 day average. It is 12% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 37), near oversold. The nearest support is the Pivot S1 at $98.20, and the nearest resistance the Pivot at $102.10.

Short trendBearish
Long trendBullish
MomentumFading
StretchNear oversold
VolatilityNormal, 3.1%/day
Key levels
$121.5052 week high+21.5%
$108.7020 day average+8.7%
$106.4050 day average+6.4%
$103.90Pivot R1+3.9%
$102.10Pivot+2.1%
$100.00Last close
$98.20Pivot S1−1.8%
$96.40Swing low−3.6%
$89.30200 day average−10.7%
$71.2052 week low−28.8%
Indicators
RSI (14)37.20Weak, oversold below 30Neutral
MACD-1.84Below its signal lineBearish
Stochastic24.5Middle of its rangeNeutral
ADX (14)21.4Weak trend
Williams %R-82.5Oversold below −80, overbought above −20Oversold
CCI (20)-121.3Oversold below −100, overbought above 100Oversold
Rate of change−6.2%Change over 10 sessionsBearish
ATR (14)$3.10Typical daily range, 3.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for ANEB

What happened before

See how ANEB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ANEB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ANEBHow many large options trades hit ANEB, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ANEB Insider Trading

All filings →
Insider trading · 12 months
No open market trades in 12 months
Bought$00 buys · 0 insiders
Sold$00 sales · 0 insiders
DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Dec 23, 2024Aron R. EnglishDirectorBuy10,101,010$0.99$10.0M
Every insider buy and sale for ANEB over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ANEB insider trades →

From SEC Form 4 filings by ANEB's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ANEB is in one of them and how their past ANEB trades turned out.

ANEB in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ANEB in an article yet. Here's the latest on the wider market.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals is a drug developer based in Lakeway, Texas, working on treatments for cannabis toxicity. Its lead candidate, selonabant, is designed to reverse the effects of cannabis intoxication and shorten recovery time. The company is focused on an intravenous version for children who have been accidentally poisoned by cannabis, with emergency departments as the intended users. Selonabant is still in clinical development and has not been approved for sale.

Headquarters
Lakeway, TX